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S U M M A R Y
Objectives: In Niger, 65% of hepatocarcinoma and 75% of cirrhosis cases were due to hepatitis B virus
(HBV). We studied the genotypic characteristics of HBsAg in chronically HBV-infected patients in
Niamey.
Methods: We studied prospectively HBV genotypic patterns among hospitalized patients with HBV
infection in the National Hospital of Niamey, Niger. Patients were screened for hepatitis B surface antigen
(HBsAg) and HBV genotyping was performed on the HBsAg-positive patients.
Results: In this study, we have conﬁrmed the predominance of the HBV genotype E (HBV-E) in Niger and
have identiﬁed 2 recombinant forms including HBV-E/D and HBV-A3/E reported previously among blood
donors in Niger and Ghana, respectively. Amino acid substitutions found in HBV sequences obtained here
included P120T, S143L, G145A and A194T. These substitutions were characterized as being associated
with modiﬁed antigenicity and, notably, with impaired serological detection of HBsAg, while the A194T
variant was found to have a controversial role in reduced susceptibility to tenofovir.
Conclusions: We have identiﬁed two recombinant HBV forms and rare genotypic patterns in Niger that
may affect hepatitis B surface antigen antigenicity, and improve current knowledge of epidemiological,
clinical and virological patterns of hepatitis B in this country.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Background
Hepatitis B virus (HBV) is a public health problem worldwide.1
An estimated 2 billion people have been in contact with the virus,
of whom 240 million are chronically infected (http://www.who.
int/mediacentre/factsheets/fs204/en/).* Corresponding author at: IHU Me´diterrane´e Infection, Fe´de´ration de Bacte´r-
iologie-Hygie`ne-Virologie, Centre Hospitalo-Universitaire Timone, 264 rue Saint-
Pierre. Marseille cedex 05, 13385, France. Tel.: +33(0)4 91 38 55 19;
fax: +33(0)4 91 38 55 19.
E-mail address: philippe.colson@ap-hm.fr (P. Colson).
http://dx.doi.org/10.1016/j.ijid.2016.02.009
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Chronic HBV infection is responsible for 60-80% of liver cancers
worldwide.1 Chronic HBV infection is spread very unevenly across
regions: in Asia, the Paciﬁc region, Sub-Saharan Africa, the
Amazonia region, Alaska, Egypt and Arabian Peninsula approxi-
mately 8-20% of the population has chronic HBV infection while in
North America, Eastern Europe and the Mediterranean basin 2-7%
of the population is infected. Finally, less than 2% of the population
has chronic hepatitis B in North America, Northern and Western
Europe and Australia. Through mass vaccination campaigns,
countries such as Singapore, Malaysia, Bahrain, Israel and Iran
have joined the group of countries with a low prevalence of
hepatitis B.2–4ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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and 250,000 of the 1.3 million HBV-related deaths recorded each
year around the world occur in Africa.5,6 The West African country
of Niger has a high prevalence of HBV. Among the 238 asymptom-
atic young students living on the campus of the University of
Niamey in 1985, 18% carried hepatitis B surface antigen (HBsAg).7
Studies conducted by Cenac et al. in 1985 and 1995 have shown
that cases of chronic liver disease in Niger including cirrhosis and
hepatocellular carcinoma are associated with HBV infection
(HBsAg pos) in 65%8 and 73%9 of cases, respectively. In addition,
Mayaki et al. found HBsAg in 15% of blood donors10 and Mamadou
et al. found a 16% prevalence rate among the 495 pregnant women
screened in 2008.11 To date, only one paper has described HBV
genotypic patterns in Niger, and it suggested the occurrence of
recombinant forms between genotypes D and E and a novel
subgenotype D (D8) strain in blood donors.12 The aim of the
present study was to describe the genotypic characteristics of
HBsAg in chronically HBV-infected patients in the National
Hospital of Niamey (NHN).
2. Study design
2.1. Patients
The ﬁrst part of this prospective study was conducted in the
National Hospital of Niamey (NHN), Niger, with authorization from
this institution. Serum samples were collected from patients older
than 18 years who were hospitalized in the internal medicine,
infectious diseases and hepato-gastroenterology units between
August 1, 2013 and February 30, 2014. After explaining the aims of
the study and the methods to be utilized, oral consent was
obtained from the patients. All patient data were reported without
divulging personal health information.
2.2. Methods
2.2.1. Data collection
Socio-demographic and clinical data were collected from the
records of hospitalized patients. The variables analyzed included
age, gender, marital status, vaccine immunization status, aspartate
aminotransferase level (AST), alanine aminotransferase level (ALT),
alpha fetal protein level (AFP), HBsAg, and HBV genotype.
2.2.2. Blood sample collection and processing
Blood samples collected in dry tubes were centrifuged and
aliquots were frozen at -40 8C at the bacteriology-virology
laboratory of the NHN. Aliquots of HBsAg-positive samples were
forwarded to Marseille for further analysis.
2.2.3. HBsAg testing
HBV surface antigen (HBsAg) detection was performed at the
NHN bacteriology-virology laboratory using the Virus Combo
Rapid test (Abon Biopharm, Co. Ltd, Hangzhou, China). HBsAg-
positive serum samples were sent to the bacteriology-virology
laboratory of Timone University Hospital in Marseille, France.
2.2.4. Determination of HBV genotype and amino acid patterns based
on the HBsAg/reverse transcriptase (RT) encoding gene
DNA extraction, ampliﬁcation and direct sequencing of the full-
length HBsAg and the reverse transcriptase (RT) genes were
performed at the bacteriology-virology laboratory of Timone
university hospital using in-house protocols as previously
described.13 Sequencing was performed using the BigDye Termi-
nator Cycle sequencing kit v1.1 (Applied-Biosystems, Branchburg,
NJ, USA) on the ABI Prism 3130 genetic analyzer (Applied-
Biosystems). HBV genotypes were determined by phylogeneticanalysis using published HBV sequences available from the
genotyping reference set available on the NCBI website (http://
www.ncbi.nlm.nih.gov/projects/genotyping/view.cgi?db=2). Se-
quence alignment was generated using the MUSCLE software14
and phylogeny reconstruction was performed by the MEGA v.5
software;15 evolutionary history was inferred using the neighbor-
joining method and evolutionary distances was determined using
the Kimura 2-parameter method. The HBsAg/RT nucleotide
sequences obtained were translated into amino acid sequences,
aligned and compared with HBV sequences of the same genotype
available in the NCBI genotyping reference set using the Microsoft
Excel software program. Amino acid patterns were analyzed using
the HBV tools from the HIV grade website (http://www.hiv-grade.
de/cms/grade/explanations/hbv-tool/). In addition, reverse tran-
scriptase or HBsAg sequences obtained from sub-Saharan blood
samples were retrieved from GenBank using the following
keywords: ‘‘hepatitis B’’[Ti] AND (‘‘hepatitis B surface antigen’’[Ti]
OR ‘‘polymerase’’[Ti] OR ‘‘reverse transcriptase’’[Ti] OR ‘‘complete
genome’’[Ti]) AND (Africa OR Algeria OR Angola OR Benin OR
Botswana OR Burkina Faso OR Burundi OR Cameroon OR Cape
Verde OR Central African Republic OR Chad OR Comoros OR Congo
OR Congo Democratic Republic OR Cote d’Ivoire OR Djibouti OR
Egypt OR Equatorial Guinea OR Eritrea OR Ethiopia OR Gabon
OR Gambia OR Ghana OR Guinea OR Guinea-Bissau OR Kenya OR
Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali
OR Mauritania OR Mauritius OR Morocco OR Mozambique OR
Namibia OR Niger OR Nigeria OR Rwanda OR Sao Tome & Principe
OR Senegal OR Seychelles OR Sierra Leone OR Somalia OR South
Africa OR South Sudan OR Sudan OR Swaziland OR Tanzania OR
Togo OR Tunisia OR Uganda OR Zambia OR Zimbabwe).
3. Results
3.1. Epidemiological and clinical observations
A total of 31 serum samples from 31 different patients tested
positive for HBsAg. The patients included 17 men and 12 women
(sex ratio, 1.3) whose mean age was 42 years [range, (21, 70)]
(Table 1); 23 were married and 7 were single, and none reported
having received the HBV vaccine. The clinicians who were taking
care of these patients were hepatogastroenterologists (for
13 patients); infectious diseases specialists (for 9 patients) and
internists (for 9 patients). End-stage liver disease including
cirrhosis and hepatocarcinoma was detected in 17 patients
(61%), was absent in 11 patients and was not documented in
3 patients. Transaminase measurement in 22 patients showed a
mean AST of 40 IU/ml [range, 8-98 (usual values: 4-45 IU/L)] and a
mean ALT of 47 UI/ml [range, 10-105 (usual values: 5-45 UI/L)].
AFP levels were found to be elevated in 5 of the 6 patients
evaluated (509 ng/ml, 456 ng/ml, 514 ng/ml, 89 ng/ml, 65 ng/ml;
normal values < 10 ng/mL).
3.2. HBV genotypes
Of the 23 HBV sequences obtained from these 31 serum
samples, 21 were classiﬁed as belonging to genotype E, one was
clustered with an A3/E recombinant (GH2537) described in Ghana
in 2000 (GenBank identiﬁer (GI): 255653196)16 and the last one
was clustered with a D/E recombinant form isolated in Niger in
2009 (isolate bne442; GI: 283466950)12 (Figure 1).
Overall, mean ( standard deviation (SD)) nucleotide identity
between the 23 HBV sequences characterized in this study and their
best match available in GenBank was 96.82.2% (range, 91.3-99.8).
The mean nucleotide identity of the 21 genotypes E HBV sequences
with their best match in GenBank was 98.80.6% (97.7-99.8) and
mean identity between each other was 97.70.08 (95.2-99.8). Among
Table 1
Main epidemiological, clinical and virological features
No. Clinical unit Gender Age (years) Marital status Ethnic group End stage
liver disease*
ALT ALT AFP Genotype Mutations
of interest
1 Int.med. M 36 Married Djerma Yes 18 23 N.a. D/E recomb. sS143L
2 HGE M 42 Married Djerma Yes 27 34 N.a. E -
3 HGE M 42 Married Djerma Yes 65 63 N.a. Neg. PCR -
4 HGE F 36 Married Haoussa Yes 18 21 N.a. Neg. PCR -
5 Inf. M 50 Married Djerma Yes 25 28 N.a. Neg. PCR -
6 Inf. M 34 Married Touareg Yes 98 105 N.a. E -
7 Int. med. M 52 Married Haoussa Yes N.a. N.a. N.a. Neg. PCR -
8 HGE M 29 Single Touareg No N.a. N.a. N.a. E -
9 Inf. F 36 Married Djerma Yes N.a. N.a. N.a. E -
10 HGE F 42 Married Haoussa Yes 16 19 N.a. E -
11 Inf. M 64 Married Haoussa No 29 36 509 E -
12 Inf. M 67 Married Touareg Yes 64 73 456 E -
13 HGE M 45 Married Haoussa Yes 53 99 89 A3/E recomb. sP120PT
14 HGE M 40 Married Djerma Yes 24 31 N.a. E -
15 HGE F 60 Married Haoussa No 8 10 4 E -
16 HGE M 37 Married Haoussa Yes N.a. N.a. N.a. E -
17 HGE M 37 Married Haoussa No 56 63 N.a. E sG145A
18 Int. med. F 41 Married Djerma No N.a. N.a. N.a. E -
19 Int. med. N.a. N.a. Married NAD N.a. N.a. N.a. N.a. E -
20 Inf. F 28 Married Haoussa Yes 15 19 N.a. Neg. PCR -
21 Inf. F 70 Single Djerma No N.a. N.a. N.a. E -
22 Int. med. F 21 Married Djerma No 16 19 N.a. E -
23 Inf. F 43 Single Peulh No 13 18 N.a. E -
24 Int. med. M 26 Single Haoussa N.a. N.a. N.a. N.a. E -
25 Int. med. F 62 Married Djerma Yes 67 75 514 E rtA194AT
26 Int. med. N.a. N.a. N.a. N.a. N.a. 64 73 N.a. Neg. PCR -
27 Inf. F 23 Single Djerma No 16 20 N.a. E -
28 HGE M 28 Single Djerma No N.a. N.a. N.a. E -
29 HGE F 57 Married Djerma Yes 58 74 N.a. Neg. PCR -
30 HGE M 34 Married Haoussa Yes 85 92 65 E -
31 Int. med. M 31 Single Haoussa No N.a. N.a. N.a. Neg. PCR -
* Cirrhosis or hepatocellular carcinoma
AFP, alpha fetal protein; ALT, alanine aminotransferase level; AST, aspartate aminotransferase level; F, female; HGE, hepatogastroenterology unit; Inf., infectious diseases
unit; M, male; Int. med., internal medicine unit; N.a., not available; Neg., negative; Rec., recombinant; rt, within the hepatitis B reverse transcriptase; s, within the hepatitis B
surface antigen
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sequence previously obtained in Niger (GI: 283466915) with a mean
identity of 99.30.4% (98.9-99.8)12 (Figure 1). Two other sequences, no.
22 and 24 were clustered with sequences obtained from Nigeria and
Cameroun, respectively. Other best hits for HBV sequences obtained
here were from Sudan17, Central African Republic (CAR097)18, Conakry
Guinea16, Niger12 (GI: 283467010, 283466950), Italy19 and Japan
(unpublished). In addition, HBV sequences that were clustered with
the HBV-A3/E and D/E recombinant forms showed a 97.7% and 98.3%
nucleotide identity with these two sequences, respectively.
3.3. Amino acid substitutions in HBsAg and reverse transcriptase
We identiﬁed HBsAg P120P/T, S143L, G145A and RT A194T
amino acid substitutions in four HBV sequences isolated in this study
(no. 013, 001, 017, 025). The ﬁrst three substitutions were found to
occur within HBsAg and have been previously described as being
associated with modiﬁed HBsAg antigenicity, with the escape to
HBsAg detection by serological methods20–22 and to vaccine
immunization.20,21,23–25 Notably, the G145A amino acid substitu-
tion was reported from a patient originating from Ivory Coast in
association with HBsAg-negativity.22 In addition, amino acid G145A
was detected in 2 (0.7%) of 292 HBsAg sequences from GenBank
that we identiﬁed as being isolated in 2007 in South Africa from
HBV-HIV-coinfected treatment-naı¨ve patients. We also noted the
presence of the A194T amino acid substitution in the reverse
transcriptase sequence of HBV isolate no. 25. Previously detected in
a sequence described in a study conducted in Conakry Guinea,16 this
mutation has been associated with decreased susceptibility to
tenofovir, but this issue remains controversial.26,27 In addition,
our search in GenBank for amino acid 194T in African reversetranscriptase sequences detected only one sequence (0.4%)
collected in South Africa from an HBV-HIV-coinfected treatment
naive patient (data unpublished).
4. Discussion
This original study is the ﬁrst analysis of genotypic patterns in
HBV isolates obtained from HBV-infected hospitalized patients in
Niger. These patients were followed-up by hepatogastroenterol-
ogists, infectiologists and internists. The only other similar study
on HBV genotypes was conducted in Niger but analyzed samples
from blood donors.12 In our study, although none of the patients
evaluated were reported as having received the HBV vaccine, it is
likely that a substantial proportion of them were infected with HBV
by mother to child transmission. This also corroborates the report
by Mamadou et al. showing that 16% of 495 pregnant women
evaluated in Niger in 2008 tested positive for HBsAg.11 Hopefully,
the hepatitis B vaccination policy introduction in 2005 in Niger as
part of an expanded immunization program will have an impact on
the incidence of HBV in younger people. Similar programs have
dramatically decreased the incidence of HBV infection in many
countries worldwide.3,4
Our data on HBV genotypes are in agreement with those obtained
from the blood donors study in 2010, showing that genotype E (HBV/
E) is the most prevalent serotype in Niger. HBV/E is also highly
prevalent in Africa and spreading in a vast crescent from Senegal to
Namibia according to previous epidemiological studies.5,28,29 In sub-
Saharan countries neighboring Niger, such as Mali, Burkina Faso,
Benin, and Nigeria, HBV/E is predominant5,28–30 whilst HBV/D is
the dominant genotype in Northern Africa.31,32 In contrast, the HBV/
A genotype is relatively rare and is found mainly in Southern, Eastern
Figure 1. Phylogenetic analysis of the HBV strains obtained in this study with reference sequences of each genotype (A–H).
The phylogenetic tree was based on a 943-nucleotide (nt) fragment of the hepatitis B virus genome encoding the reverse transcriptase/hepatitis B surface antigen (nt 131–
1,073 in the reference sequence, GenBank accession no. AF405706). The HBV DNA from isolates obtained in this study is indicated by a boldface white font on a black
background. Other sequence names in boldface indicate sequences with the highest BLAST scores (http://blast.ncbi.nlm.nih.gov/Blast.cgi) found in the NCBI GenBank
nucleotide sequence database. Reference sequences with known genotypes and subtypes are indicated. Nucleotide sequence alignments were performed using ClustalX
version 2.0 (www. clustal.org/download/current). The tree was constructed by using MEGA5 (www.megasoftware.net) and the neighbor-joining method. Branches were
obtained from 1,000 resamplings of the data; those with bootstrap values >50% are labeled on the tree. Scale bar indicates nucleotide substitutions per site. BBH, best BLAST
hit.
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and a potential new subgenotype identiﬁed in Rwanda have been
reported.33 Recombinant forms between HBV/A and HBV/E have
been described in subSaharan Africa.34,35 Several studies have also
described recombinant forms between HBV/A and D in Northern
Africa and Southern Africa.34 It has been previously reported that
HBV/E from Niger exhibited greater genetic variability than
generally described in Africa.12 In the present study, we observed
that HBV/E sequences obtained from samples collected in Niger
were scattered in the phylogenetic tree among those from other
subSaharan countries (Sudan, Central African Republic, Cameroun,
Guinea Conakry and Nigeria), and maximal nucleotide divergence
with their best BLAST hit among HBV/E sequences obtained in
subSaharan Africa was 3.1%; some of the HBV/E sequences obtained
here were clustered conﬁdently with HBV/E sequences described
in Niger, Nigeria and Cameroun. In addition, we identiﬁed two
sequences that matched with HBV recombinant forms. The ﬁrst
one is the HBV E/D recombinant (bne442; GI: 283467010) reported
in the study by Abdou Chekaraou et al. using samples from blood
donors in Niger12 and the second one is the HBV A3/E recombinant
(GH2537) reported in Ghana, also in blood donors.16 These
circulating recombinant HBV isolates identiﬁed in Ghana and in
Niger might be explained by the mixing of HBV-infected populations
over several decades. Indeed, a large Nigerian traders community is
present in Ghana and vice versa.
The core region of HBsAg comprises the major hydrophilic
region (MHR) that is exposed at the virus surface and spans amino
acids 99-169 including amino acids 124-147 that correspond to
the ‘‘a’’ determinant, which comprises two loops and is the major
target of neutralizing antibodies.23,36 Antibodies found in vacci-
nated people and those used in HBsAg immunoassays are directed
speciﬁcally against this region.23,36 Amino acid substitutions
P120T, S143L and G145A detected in this study in Nigerian HBV
sequences may contribute to altered HBsAg antigenicity and
therefore, to potentially missed hepatitis B diagnosis, thus
lowering the prevalence of HBsAg carriers. Although these amino
acid substitutions were identiﬁed in HBsAg-positive patients, they
may lead to signiﬁcant modiﬁcations in HBsAg antigenicity in
combination with other mutations.20–22 Moreover, although none
of the patients evaluated in the present study reported having
received HBV vaccine, HBsAg amino acid substitutions that were
detected were previously associated with vaccine escape.20,21,23–25
The A194T substitution found in one HBV reverse transcriptase
sequence in this study has been previously suspected to be
associated with resistance to the anti-HBV drug tenofovir,
available in Niger and many other sub-Saharan countries,
particularly in cases of co-infection with HIV.27,37,38 Interestingly,
Sheldon et al. reported the selection of the A194T HBV mutant in
association with lamivudine drug-resistance in individuals who
were co-infected with HBV and HIV-1 and had failed tenofovir
therapy,38 but this mutation was not further conﬁrmed as
conferring reduced tenofovir susceptibility. Moreover, the HBV
A194T mutation in RT was previously observed in the absence of
anti-HBV drug pressure at a frequency of 0.1%, 0.2%, 0.3% and 3.7%
in HBV genotypes C, D, E, and H, respectively, and from drug naive
blood donors from Conakry Guinea.27 In addition, we detected
residue 194T in another African sequence retrieved from GenBank
that was obtained in South Africa.
In summary, this study identiﬁed two recombinant HBV forms
and rare genotypic patterns in Niger that may affect the serological
diagnosis of hepatitis B and improve current knowledge regarding
the epidemiological, clinical and virological patterns of hepatitis B
in this country.
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